Our results show that the frequency of inactivating CDKN2A/RB1 alterations is highest after tumor progression following post-operative combination therapy, and PDGFRA/MET alterations co-appear with CDKN2A inactivation. This evidence concerns the gene CDKN2A and neoplasm.